Poison ivy

Related Terms

African poison ivy, Anacardiaceae (family), heptadecylcatechol (HDC) diacetate, oleoresin, pentadecylcatechols, rhus radicans, Toxicodendron radicans, Toxicodendron radicans resin, urushiol.
Note: This monograph covers poison ivy (Toxicodendron radicans) only; poison oak, sumac, and other members of Anacardiaceae family are covered in other monographs.

Background

Poison ivy (Toxicodendron radicans) is a plant native to North America that grows well in most areas. Its leaves are arranged in groups of three and vary in size and color during the season. In spring to summer, the leaves are small and red, eventually turning green, glossy, and smooth. In the fall, the leaves may turn red, orange, yellow, or brown.
Poison ivy contains compounds that cause allergic reactions. In the United States and Canada, poison ivy is one of the most common causes of skin rash. Potentially serious reactions may result when poison ivy is used on the skin or eyes or if it is taken by mouth or inhaled.

Evidence Table

These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. GRADE *
These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. GRADE *
* Key to grades

A: Strong scientific evidence for this use
B: Good scientific evidence for this use
C: Unclear scientific evidence for this use
D: Fair scientific evidence for this use (it may not work)
F: Strong scientific evidence against this use (it likley does not work)
* Key to grades

A: Strong scientific evidence for this use
B: Good scientific evidence for this use
C: Unclear scientific evidence for this use
D: Fair scientific evidence for this use (it may not work)
F: Strong scientific evidence against this use (it likley does not work)

Tradition / Theory

The below uses are based on tradition, scientific theories, or limited research. They often have not been thoroughly tested in humans, and safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. There may be other proposed uses that are not listed below.

Dosing

Adults (18 years and older)
There is no proven safer or effective dose of poison ivy in adults.

Safety

The U.S. Food and Drug Administration does not strictly regulate herbs and supplements. There is no guarantee of strength, purity or safety of products, and effects may vary. You should always read product labels. If you have a medical condition, or are taking other drugs, herbs, or supplements, you should speak with a qualified healthcare provider before starting a new therapy. Consult a healthcare provider immediately if you experience side effects.

Interactions

Interactions with Drugs
Poison ivy may interact with anticancer drugs.

Attribution

This information is based on a systematic review of scientific literature edited and peer-reviewed by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com).

Bibliography

Amrol D, Keitel D, Hagaman D, et al. Topical pimecrolimus in the treatment of human allergic contact dermatitis. Ann Allergy Asthma Immunol 2003;91(6):563-566.
Briant D, Brouder G. Identification and treatment of poison ivy dermatitis. Nurse Pract 1983;8(7):13, 16, 19.
Canavan D, Yarnell E. Successful treatment of poison oak dermatitis treated with spp. (Gumweed). J Altern Complement Med 2005;11(4):709-710.
Cardinali C, Francalanci S, Giomi B, et al. Contact dermatitis from in a homeopathic remedy. J Am Acad Dermatol 2004;50(1):150-151.
Cardinali C, Francalanci S, Giomi B, et al. Systemic contact dermatitis from herbal and homeopathic preparations used for herpes virus treatment. Acta Derm Venereol 2004;84(3):223-226.
Davenport P, Land KJ. Isolation of Leclercia adecarboxylata from the blood culture of an asymptomatic platelet donor. Transfusion 2007;47(10):1816-1819.
Gladman AC. dermatitis: poison ivy, oak, and sumac. Wilderness Environ Med 2006;17(2):120-128.
Grater WC. Hypersensitivity dermatitis from American weeds other than poison ivy. Ann Allergy 1975;35(3):159-164.
Hershko K, Weinberg I, Ingber, A. Exploring the mango-poison ivy connection: the riddle of discriminative plant dermatitis. Contact Dermatitis 2005;52(1):3-5.
Johnson RA, Haer H, Kirkpatrick CH, et al. Comparison of the contact allergenicity of the four pentadecylcatechols derived from poison ivy urushiol in human subjects. J Allergy Clin Immunol 1972;49(1):27-35.
Mohan JE, Ziska, LH, Schlesinger WH, et al. Biomass and toxicity responses of poison ivy () to elevated atmospheric CO2. Proc Natl Acad Sci USA 2006;103(24):9086-9089.
Oka K, Saito F, Yasuhara, T, et al. A study of cross-reactions between mango contact allergens and urushiol. Contact Dermatitis 2004;51(5-6):292-296.
Skin protectant drug products for over-the-counter human use; final monograph. Final rule. Fed Regist;2003;68(107):33362-33381.
Werchniak AE, Schwarzenberger K. Poison ivy: an underreported cause of erythema multiforme. J Am Acad Dermatol 2004;51(5 Suppl):S159-S160.
Wooldridge WE. Acute allergic contact dermatitis. How to manage severe cases. Postgrad Med 1990;87(4):221-224.